Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone propionate + albuterol fixed-dose combination for prevention of severe asthma exacerbations
2023-505435-12-00Phase 3Authorised
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of fluticasone propionate and salbutamol in asthma (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Time to first severe clinically important asthma exacerbation. Planned start Mar 2024; status: authorised.
02
Drugs
fluticasone propionatesalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on 2023-505435-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505435-12-00.